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resumen
introducción: La 3,4-Methylenedioxypyrovalerone (mdpV) es un componente de las 
denominadas sales de baño, aparecidas en el mercado a final de la década del 2000 
debido a la falta de precursores de síntesis de mdmA, y su uso va en aumento. El ob-
jetivo de este trabajo es clarificar sus características farmacológicas y potencialidades 
adictivas. método: Mediante búsquedas en PubMed, 21 estudios relacionados con la 
química, farmacología o potencial adictivo del mdpV fueron seleccionados. resulta-
dos: El mdpV muestra ser capaz de inducir una potente hiperlocomoción, preferencias 
condicionadas, sensibilización conductual, autoadministración y altos puntos de corte 
en pruebas de razón progresiva. Conclusión: Los estudios revisados apuntan a que 
el mdpV es un potente psicoestimulante con un potencial adictivo similar al de la cocaí-
na o la metanfetamina. Su abuso continuado podría llevar a una epidemia de adictos 
al mdpV. 
palabras clave: mdpV, sales de baño, preferencia condicionada, autoadministración, 
razón progresiva.
Abstract 
introduction: 3,4-Methylenedioxypyrovalerone (mdpV) is a major component of the new 
psychoactive substances termed “bath salts”. These substances appeared on the drug 
market at the end of the last century given the lack of mdmA precursors, caused by its 
worldwide prosecution by governments and police agencies, and its growing use. The 
goal of this work was to clarify its pharmacological features and addiction-like potentiali-
ties. methods: By PubMed searches, 21 studies related to mdpV chemistry, pharmaco-
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logy or addictive features were selected. results: mdpV is seen to be able to induce 
potent hyperlocomotion, conditioned place preference, behavioural sensitisation, self-
administration and high breakpoints in progressive ratio schedules. Conclusion: The 
reviewed studies indicate that mdpV is a powerful psychostimulant with a similar addictive 
potential to that of cocaine or methamphetamine. Its abuse can lead to an epidemic of 
mdpV addicts.
keywords: mdpV, bath salts, conditioned preference, self-administration, hyperlocomo-
tion, progressive ratio.
introduction 
3,4-Methylenedioxypyrovalerone (1-(3,4-Methylenedioxyphenyl)-2-pyrrolidinylpentan-1-
one, mdpV) is a designer drug recently appeared on the market, normally sold as bath salts or 
fertilizers on the Internet (Penders and Gestring, 2011; Smith et al., 2011). Despite its recent 
appearance on the illegal drug market, this molecule, along with other analogues, was pat-
ented in 1969 by the German pharmaceutical company Boehringer Ingelheim as a centrally 
acting stimulant (de Felice et al., 2014) with potential as a possible treatment as narcolepsy 
and chronic fatigue. For this purpose came to market (Goldberg et al., 1973), but the abuse of 
it by addicts made it being withdrawn from circulation (Deniker et al., 1975). It is a synthetic 
derivative of cathinone, an amphetamine-like stimulant that has been used for thousands of 
years in Eastern Africa and in the Arabian countries (Kalix, 1992). From this molecule are de-
rived the majority of drugs that comprise products sold as bath salts, among which we highlight, 
besides methylenedioxypyrovalerone, other substances such as mephedrone or methylone 
(Marusich et al., 2012). A tendency of increase in its consumption patterns as reflected by the 
data of seizures of this substance (unodc, 2013). In addition, in some areas of Northern and 
Central Europe the consequences of its use are already beginning to suppose serious medical 
and social problems (Csáki et al., 2013; Simonsen et al., 2015). Therefore, our goal is to pro-
vide a brief explanation of mdpV’s chemical properties and review the locomotor activating ef-
fects and addiction-like features of mdpV that have been assessed in preclinical studies, while 
comparing them with classic addictive drugs. 
methods
The following PubMed searches were performed: “mdpV And chemistry”, “mdpV And loco-
motion”, “mdpV And preference”, “mdpV And self-administration” and “mdpV And sensitization”. 
After removing duplicates and critically revising all the search results, 21 studies were selected 
out of 129 potential results.
results
The chemical properties of this drug are the following: Its name is (R / S) -1- (Benzo [d] 
[1,3] dioxol-5-yl) -2- (pyrrolidin- 1-yl) pentane-1-one; the molecular formula is, in the freebase 
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form, C16H21NO3, it has a molecular weight of 275.35 grams per mol of mdpV and a melting point 
for the mdpV hydrochloride of between 238 and 239ºC (Yohannan et al., 2010). Pure mdpV hci 
is presented as a white crystalline powder. This form is highly soluble in water, but it also 
proves to be in methanol and chloroform. On the other hand, freebase mdpV is a non-crystalline 
powder which colors range from brown to yellow or green (Yohannan et al., 2010). The differ-
ences between mdpV isomers, which occurs due to the presence of a carbon atom that acts as 
a chiral center, there were no published data on this subject until recently. However, a very 
recent study conducted by Kolanos et al. (2015) addressed this issue. Reuptake inhibition of 
the dopamine transporter (dAt) assays showed an effect 10 times higher of s(+)mdpV on the 
other enantiomer. Additionally, an analysis of the facilitation of the intracranial self-stimulation 
thresholds shows that r(-)mdpV is unable to provide it, even at a dose 100 times superior to 
the minimum effective to facilitate the stimulation of s(+)mdpV. Such results indicate that neu-
rochemical and possibly behavioral effects of racemic mdpV are strongly mediated by the s(+) 
enantiomer. 
In structural terms, this cathinone shares, in addition to the previously mentioned ketone 
group present in all cathinones, similarities with mdmA as it also owns a 3.4-methylenedioxy 
group, but is the presence of pyrrolidine group, together with the amino tertiary amino group 
which make this molecule less polar and highly lipophilic. Because of that, mdpV readily cross-
es the blood-brain barrier and it can exert their powerful psychoactive effects (Coppola and 
Mondola, 2012; Kolanos et al., 2013).
Regarding its in vivo pharmacological effects, it is well known that all addictive drugs, 
especially psychostimulants, have the ability of provoking hyperlocomotion by direct or indirect 
stimulation of the mesolimbic dopamine system (Wise and Bozarth, 1987). This property of 
mdpV has been quite extensively studied in recent years. As an example, the study conducted 
by Marusich et al. (2012) shows, using a functional observational battery, that mdpV produces, 
in mice, different types of stereotyped movements, such as circular, non-circular head move-
ments and compulsive stereotyped movements. Another study in which mdpV-induced stereo-
typies are evaluated is the one from Aarde et al. (2013), who report that such stereotypies 
appeared when the drug was both yoked-administered and self-administered. 
There are also a number of studies which assess mdpV-induced hyperlocomotion putting 
the animal in an open field where the horizontal distance traveled or the number of cut ir ray 
beams in a given period of time are counted. In this sense, the study by Aarde et al. (2013) 
shows that mdpV is able to induce locomotor activity in rats with similar potency to that of meth-
amphetamine (meth) at doses of 0.5, 1 and 3.2 mg/kg, but the 5.6 mg/kg mdpV dose caused 
greater hyperlocomotion than the same dose of meth.
In the aforementioned study by Marusich et al. (2012) hyperlocomotion induced by differ-
ent doses of mdpV was also analyzed. All four doses (1, 3, 10 and 17 mg/kg) showed a sig-
nificant increase locomotor activity. Also in this regard, Fantegrossi et al. (2013) also demon-
strated a significant increase in activity, although this effect showed to be biphasic when the 
animal is placed at high room temperature (28ºC).
We can also highlight the study of Baumann et al. (2013), which compares the ability of 
mdpV and cocaine to induce locomotor activity in rats. The synthetic cathinone shows that a 
higher power than cocaine even at lower doses. These data are accompanied by microdialysis 
results that show mdpV is 10 times more potent than cocaine in increasing extracellular 
dopamine levels in the nucleus accumbens, a central part of the dopaminergic mesolimbic 
system on which all addictive drugs more or less directly act (Koob and Volkow, 2010).
We will discuss now the paradigms that have been traditionally used to study properties 
of addictive drugs, or other experiments that model some of the hallmarks of the addict. Also 
note that addiction, as of today, is considered a chronic and relapsing mental illness character-
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ized by compulsive drug seeking and taking that ends up in a loss of control over the amount 
of drug consumed. It is considered a mental disease because the continued use of the drug 
causes changes in brain function that can be long-lasting or even permanent (nidA, 2014). 
Such changes are supposed to be, in turn, responsible for maintaining the pattern of compul-
sive drug seeking and taking characteristic of the addict. Of all models or tests used in the 
study of properties rewarding properties, conditioned preference procedures are arguably the 
most used ones. In these procedures, the experimental subject associates drug administration 
with a particular stimulus, by means of pairing of both of them repeatedly on alternate days. 
On the other days, saline administration is paired with a different stimulus. Once the drug ad-
ministration cycle has been fulfilled the animal is tested, leaving him free access to both stim-
uli and recording the time spent with each one. A significant increase in the time the animal 
spends with the stimulus associated with the drug is interpreted as the substance administered 
during the previous phase is rewarding.
However, this inference is not uniquely accepted by the scientific community (Bardo and 
Bevins, 2000; Sanchis-Segura and Spanagel, 2006), and alternative interpretations have been 
proposed (Mead et al., 2005). Nevertheless, it is a fact that addictive drugs, in a certain dose 
range, have the ability to elicit this approach response towards the stimulus that have been 
paired with (Carbo-Gas et al., 2014; Braida et al., 2004). MDPV also shows this effect. There 
are two studies using this paradigm to evaluate these properties of this substance. One of 
them, led by King and colleagues in 2015 showed that the three tested doses (1-3.2 mg/kg) 
had the ability to elicit this response in rats. However, a not-so-recent study looks at the ability 
of different cathinones to set such preferences in mice, and were also compared to a classic 
addictive drug as amphetamine. Results show that mdpV was the only cathinone able to estab-
lish conditioned preference at all doses tested (0.5-20 mg/kg), while amphetamine was not 
able to elicit it in doses lower than 10 mg/kg (Karlsson et al., 2014).
Sensitization is a progressive increase of a drug effect caused by a repeated and inter-
mittent drug administration. This theory suggests that the repeated exposure to a drug may 
cause a sensitization (hyperactivation) of the mesolimbic dopaminergic system. Such drug-in-
duced sensitization makes drug users being more reactive to the drug and drug-associated 
stimuli. This system is responsible, in the authors’ opinion, for attributing incentive or motiva-
tional value of stimuli from the environment, and it causes that those stimuli are becoming more 
and more wanted, although hedonic value or pleasurable properties of these stimuli may not 
increase or even develop tolerance (Robinson and Berridge, 2008).
When modeling sensitization, especially to pychostimulants such as mdpV, an effect that 
is observed and has been described repeatedly is the ability to induce the so-called psychomo-
tor sensitization, this is, a gradual and persistent increase in locomotor stimulating effects such 
as locomotor activity or rotational movements or stereotyped behaviors (Robinson and Ber-
ridge, 2000).
There is one study that assessed the development and expression of behavioral sensiti-
zation to mdpV (Buenrostro-Jauregui et al., 2016) and it showed that 5 doses of 0.3 mg/kg are 
sufficient to induce a lasting locomotor sensitization as well as cross-sensitization with co-
caine. 
Self-administration studies have also been carried out with mdpV. Based on operant con-
ditioning, developed by Skinner’s work and according to which, if a response is contingently 
accompanied by the administration of a substance with reinforcing properties, the probability 
that the subject performs the response again will be increased (Skinner, 1938). Nevertheless, 
within this technique, changing certain conditions such as the number of responses to be per-
formed by the subject to get a reinforce dose or the length of the training session various as-
pects of addiction, that will be discussed later, are modeled. Now we will focus on studies in 
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which the reinforce is mdpV and requirements for obtaining dose are constant and low-demand-
ing and self-administration sessions are relatively short, which are best suited to measure only 
the reinforcing effects of a substance. In this regard the work of Watterson et al. (2012) shows 
that the self-administration of mdpV was quickly achieved and in a similar manner to metham-
phetamine in rats. However, the work by Aarde et al. (2013) also compared the self-adminis-
tration of methamphetamine and mdpV, and during the acquisition phase the number of drug 
infusions per hour was higher in the animals that received mdpV than those who received meth-
amphetamine, but further analysis showed no statistical significant difference in the total 
amount of drug obtained for animals treated with either substance. More evidence in favor of 
the addictive potential of mdpV was revealed in the work by Aarde et al. in 2014, which showed 
that access to a reinforcing activity for the rats such as giving them access to a “running wheel” 
(Belke, 2004) did not reduce significantly the ratio self-administration of this substance in rats, 
while access to this device decreases self-administration behavior of other drugs (Cosgrove et 
al., 2002; McMillan et al., 1995; Miller et al., 2012). 
The following kind of self-administration studies we mention are the so-called progressive 
ratio studies. In these studies requirements to obtain the dose of drug or reinforcer are in-
creased, usually following an arithmetic progression or similar (Richardson and Roberts, 1996). 
However, if the interpretation of results focuses on the experimental subject, the breakpoints 
(requirement the animal fulfills to get the last dose of drug) can be interpreted as an index of 
motivation of the subject for getting the reinforcer (Deroche-Gamonet and Piazza, 2014). We 
found three studies that apply this technique using mdpV as the substance administered, but 
due to procedural differences is difficult to compare them with each other. Despite this, the 
work of Watterson et al. (2012) compared the results of various doses of methamphetamine 
with MDPV and looked at the dose both drugs shared (0.05 mg/kg/inf) some breakpoints for 
mdpV were higher, although the difference was not significant. Another study (Aarde et al., 
2013) compared breakpoints for different doses of mdpV and meth, and it showed that, for 
doses of 0.05 and 0.1 mg/kg/inf rats produced significantly more responses on the drug-asso-
ciated lever for mdpV than for meth.
Conclusions
The reviewed studies show that mdpV is a potent psychostimulant, which causes greater 
hyperlocomotion than cocaine and similar to meth. Additionally, it is able to set conditioned 
preferences within a wide range of doses, greater than those of amphetamine. Moreover, it has 
also been reported that it can induce behavioral sensitization with a very low dose, and self-
administration studies show its reinforcing properties. Interestingly, progressive ratio studies 
revealed that rats that self-administer mdpV also showed a great motivation for obtaining the 
drug, and additionally, wheel running access did not reduce mdpV self-administration rates. 
Taken together, these findings show that mdpV accomplishes all behavioral features that addic-
tive psychostimulants do, but there are also some of findings like the low dose required to in-
duce sensitization, how readily rats acquire mdpV self-administration behavior, the higher 
breaking points than those found with meth, and the lack of effect of running wheel access, that 
hint at a greater addictive potential. More studies, however, including models that accomplish 
several behavioral features reminiscent of the human addicts (Deroche-Gamonet and Piazza, 
2014) would be useful in order to further enlighten the issue.
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